Researchers still don’t fully understand the cause of multiple sclerosis or why the rate of progression is so difficult to ...

Ocrevus appears to be a safe and effective treatment for children and adolescents with MS, according to real-world data from ...

A second-generation anti-CD40 therapy that inhibits B- and T-cell activity nearly eliminated multiple sclerosis activity over ...

RRMS is the most common type of multiple sclerosis ... including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

The initial proceeds to Immunic from the offering were approximately $65 million, before deducting underwriting discounts and commissions and offering expenses. The Company may receive up to an ...

Have a listen to Dale Husbands Korero with Neil Woodhams ...

In this randomized controlled trial of patients with nonrelapsing secondary progressive multiple sclerosis (SPMS), oral ...

Despite its growing role in tracking MS activity, serum neurofilament light chain lacks diagnostic specificity, experts say.

Alvotech is expanding its partnership with Advanz Pharma to commercialize new products in Europe, including a Kesimpta biosimilar drug for MS.

We spoke to MS Australia, a national not-for-profit organisation dedicated to improving the lives of those affected by ...

Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.